Media Release

Veyonda® Research to be Shared at Two Major Oncology Conferences Enhancing Radiotherapy in Prostate Cancer Treatment

- **Australian drug development company Noxopharm™ to present interim results on new prostate cancer treatment at specialist oncology conferences in Australia and overseas**

SYDNEY, 12 Sept 2019
Noxopharm™ Ltd (ASX: NOX) (‘**Noxopharm’** or the ‘**Company’**) today announced that scientific abstracts on interim data relating to its DARRT-1 prostate cancer treatment study have been accepted for inclusion in two major oncology conferences. These are clinical forums where all abstracts are peer reviewed by oncologists before being included in the program.

Interim results from the DARRT-1 study were first released to financial markets earlier this year. Now these results will be communicated to specialist oncologists in Australia and overseas.

These results showed that patients who were treated with the Company’s proprietary treatment Veyonda® combined with radiotherapy had a durable anti-cancer response rate lasting at least 6 months (the length of the study) in a high proportion of men with end-stage, metastatic, castration-resistant prostate cancer (mCRCP).

The DARRT-1 interim results will be displayed in a poster presentation at the Clinical Oncology Society of Australia (COSA) annual scientific meeting in November this year. Also, of interest to attendees will be the poster presentation by St Vincents Hospital, Sydney related to their LuPIN study. This study is an investigator-initiated clinical trial looking at the effect of Veyonda in combination with a new cancer treatment ^{177}LuPSMA-617 in men with mCRPC.

Noxopharm will also have an e-publication on the DARRT-1 interim results included in the proceedings for the annual meeting of the Chinese Society of Clinical Oncology (CSCO) commencing on 19 Sept, 2019. The CSCO has over 10,000 members and this meeting includes international sessions that present the latest cancer care strategy and research results.

Greg van Wyk, Noxopharm CEO and Chief Medical Officer, said: ‘Inclusion of our DARRT-1 study results in these important medical conferences is indeed validation of the work we have underway. Our abstracts have been peer-reviewed and found to be of value to oncologists both in Australia and overseas.’

About Veyonda®

Veyonda® (previously known as NOX66) is a suppository dosage formulation of the experimental anti-cancer drug, idronoxil, that leads in the body to the formation of a proprietary pro-drug form. Idronoxil specifically inhibits the ability of cancer cells to respond to stress, such as that induced by radiation, leading to loss of pro-survival signalling via sphingosine-1-phosphate. Idronoxil also promotes the STING mechanism, thereby activating the body's innate immune system.

About the DARRT program

The Company's DARRT (Direct and Abscopal Response to Radiotherapy) Program is testing the ability of Veyonda® to increase tumour response to radiotherapy. The rationale of DARRT is to take advantage of the radio-enhancing properties of Veyonda® that stem from its inhibition of sphingosine-1-phosphate pro-survival functions, combined with its ability to stimulate the body's first line immune defence cells against cancer. The clinical outcome being sought is PSA and pain reductions as well as greater shrinkage of irradiated tumours and shrinkage of non-irradiated tumours (abscopal response). The DARRT treatment regimen is being tested initially in prostate cancer, but in due course is to be extended into other forms of solid cancer that the Company believes will assist the Veyonda® marketing approval process.

About DARRT-1

DARRT-1 is a Phase 1b 26-subject study being conducted in Georgia and Australia. The study is in 2 arms, with 14 subjects in the first arm and 12 in the second. The first arm is for dose-finding entailing 3 cohorts receiving 400 mg, 800 mg and 1200 mg Veyonda® respectively. In the second arm, all subjects are receiving the 1200 mg Veyonda® dose. The DARRT treatment regimen entails a 5-day course of radiotherapy (20 Gy) with Veyonda® administered daily for up to 2 weeks. The subjects are being assessed clinically at 6-, 12- and 24- weeks.

About Noxopharm

Noxopharm is a clinical-stage Australian drug development company with offices in Sydney and New York. The Company has a primary focus on the development of Veyonda® and is the major shareholder in Nyrada Inc, a spin-off company developing a pipeline of non-oncology drugs.

Media Contact USA:
Frank de Maria
Purposeful Communications
T: +1 347 647 0284
E: frank.demaria@purposefulcommunications.com

Media Contact Australia
Marianne Gould
Noxopharm Ltd
T: +61 2 9144 2223
E: Marianne.gould@noxopharm.com

www.noxopharm.com